After retail pharmacy closures, health systems enter new markets
(By Paige Twenter for Becker’s Hospital Review) As CVS, Walgreens and Rite Aid close hundreds of pharmacies across the U.S.
Read More
Part D/Prescription Drugs
Drugmakers and pharmacists battle over who gets to make obesity drugs
(By Sydney Lupkin for NPR) Ozempic and similar drugs for Type 2 diabetes and weight loss are in such high
Read MoreFuture of Medicare drug price negotiations under new administration: 5 things to know
(By Alexandra Murphy for Becker’s Hospital Review) As President-elect Donald Trump prepares to take office, the future of Medicare’s drug
Read MoreMedicare Advantage 2025 Spotlight: A First Look at Plan Premiums and Benefits
(By Meredith Freed, Jeannie Fuglesten Biniek, Anthony Damico, and Tricia Neuman for The Kaiser Family Foundation Published: Nov 15, 2024)
Read More5 benefits Medicare Advantage plans are cutting back for 2025
(By Rylee Wilson for Becker’s Hospital Review) Fewer Medicare Advantage insurers will offer remote access technologies and over-the-counter benefits in
Read MoreMedicare Advantage saves money
Medicare recipients who migrate from traditional Medicare to the Medicare Advantage program have saved the federal government $144 billion over
Read MoreIs a Medicare Advantage plan right for you?
It is the time of the year again when all those Medicare Advantage plans advertise how wonderful they are and
Read More2025 Medicare Parts A & B Premiums and Deductibles
(Source – www.cms.gov) The Centers for Medicare and Medicaid Services (CMS) has released the 2025 premiums, deductibles, and coinsurance amounts
Read MoreFDA adds warning to Ozempic, Mounjaro and other GLP-1 labels
(By Alexandra Murphy for Becker’s Hospital Review) The FDA has updated the labels for all GLP-1 receptor agonists, including popular
Read MoreMedicaid Coverage of and Spending on GLP-1s
(By Elizabeth Williams, Robin Rudowitz, and Clea Bell for The Kaiser Family Foundation Published: Nov 04, 2024) GLP-1 (glucagon-like peptide-1)
Read More